Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > panobinostat, lomustine, xB3-bevacizumab
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(115)
•••
Comment by prophetoffactzon Dec 16, 2022 2:10pm
92 Views
Post# 35176403

RE:RE:panobinostat, lomustine, xB3-bevacizumab

RE:RE:panobinostat, lomustine, xB3-bevacizumab"Yes, there is reason to believe that Biodexa will survive. They will have a compelling pipeline."

xB3 has never been in a stronger position.
 
With Biodexa a multi-asset clinical stage company able to take assets into clinical trials on its own, if xB3 is validated by J&J in the next approximately 30 business days through the multi-product option exercise this company can look increasingly impressive. Then the new Hunter preclinical data, potentially in Q2 2023 as Chiesi also potentially receives approval for Fabry becoming a strategic player in LSDs. Could a second strategic deal be near for the other LSDs currently not in the BTI/Chiesi deal? Biodexa will be able to develop the LSDs itself and not have to given them away immediately for a minimal royalty. Then there is a potential cancer strategic alliance. We need to see a Saltarelli out of this. 
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities